PLoS Pathogens | |
Forward Genetic Screening Identifies a Small Molecule That Blocks Toxoplasma gondii Growth by Inhibiting Both Host- and Parasite-Encoded Kinases | |
Graham B. Wiley1  Patrick M. Gaffney1  Marc Jan Gubbels2  Andrew Farrell2  Gabor Marth2  Aaron McLain3  Ashley Dittmar3  Kevin M. Brown4  Ira J. Blader4  Elena Suvorova5  Michael White5  | |
[1] Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States of America;Department of Biology, Boston College, Chestnut Hill, Massachusetts, United States of America;Department of Microbiology and Immunology, University at Buffalo, Buffalo, New York, United States of America;Department of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America;Departments of Molecular Medicine & Global Health, University of South Florida, Tampa, Florida, United States of America | |
关键词: Parasite replication; Parasitic diseases; Toxoplasma; Kinase inhibitors; Tachyzoites; Host cells; Parasitic cell cycles; Vacuoles; | |
DOI : 10.1371/journal.ppat.1004180 | |
学科分类:生物科学(综合) | |
来源: Public Library of Science | |
【 摘 要 】
The simultaneous targeting of host and pathogen processes represents an untapped approach for the treatment of intracellular infections. Hypoxia-inducible factor-1 (HIF-1) is a host cell transcription factor that is activated by and required for the growth of the intracellular protozoan parasite Toxoplasma gondii at physiological oxygen levels. Parasite activation of HIF-1 is blocked by inhibiting the family of closely related Activin-Like Kinase (ALK) host cell receptors ALK4, ALK5, and ALK7, which was determined in part by use of an ALK4,5,7 inhibitor named SB505124. Besides inhibiting HIF-1 activation, SB505124 also potently blocks parasite replication under normoxic conditions. To determine whether SB505124 inhibition of parasite growth was exclusively due to inhibition of ALK4,5,7 or because the drug inhibited a second kinase, SB505124-resistant parasites were isolated by chemical mutagenesis. Whole-genome sequencing of these mutants revealed mutations in the Toxoplasma MAP kinase, TgMAPK1. Allelic replacement of mutant TgMAPK1 alleles into wild-type parasites was sufficient to confer SB505124 resistance. SB505124 independently impacts TgMAPK1 and ALK4,5,7 signaling since drug resistant parasites could not activate HIF-1 in the presence of SB505124 or grow in HIF-1 deficient cells. In addition, TgMAPK1 kinase activity is inhibited by SB505124. Finally, mice treated with SB505124 had significantly lower tissue burdens following Toxoplasma infection. These data therefore identify SB505124 as a novel small molecule inhibitor that acts by inhibiting two distinct targets, host HIF-1 and TgMAPK1.
【 授权许可】
CC BY
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO201902011869938ZK.pdf | 1728KB | download |